Bladder Cancer Journal Vol. 10, Issue 1
Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle...
Read MoreSelect Page
by Bladder Cancer Journal | Mar 2024
Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle...
Read Moreby Bladder Cancer Journal | Dec 2023
What is a Bladder Cancer Molecular Subtype? Abstract:Â BACKGROUND: Several molecular...
Read Moreby Bladder Cancer Journal | Sep 2023
Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is...
Read Moreby Bladder Cancer Journal | Jun 2023
Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer...
Read Moreby Seth P. Lerner, MD | Apr 2023
Seth P. Lerner, MD, discusses the optimal therapy for T1 high-grade (T1HG) bladder cancer and considers the future of treatment.
Read Moreby Bladder Cancer Journal | Mar 2023
Recent Advances in the Classification of Bladder Cancer – Updates from the 5th Edition of the...
Read Moreby Seth P. Lerner, MD | Feb 2023
In this 20-minute video, Seth P. Lerner, MD, Professor of Urology and Vice-chair for Faculty Affairs in the Scott Department of Urology, and Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program at Baylor University, discusses risk-adapted transurethral resection of bladder tumor (TURBT). He assesses TURBT’s role in staging and treatment and considers its use in bladder preservation.
Read Moreby Daniel A. Hamstra, MD, PhD | Feb 2023
In this 24-minute video, Daniel A. Hamstra, MD, PhD, Professor and Chair of Radiation Oncology at Baylor College of Medicine, discusses the viable but under-utilized therapy of trimodal bladder preservation. He specifically explores the role of surgery, chemotherapy, radiotherapy (RT), and check-point inhibitors in bladder sparing therapy.
Read Moreby Bladder Cancer Journal | Dec 2022
Predicting Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer:...
Read Moreby Bladder Cancer Journal | Sep 2022
Mechanism of Sex Differences in Bladder Cancer: Evident and Elusive Sex-biasing Factors Abstract:Â ...
Read Moreby Bladder Cancer Journal | Jun 2022
Role of Chromatin Modifying Complexes and Therapeutic Opportunities in Bladder Cancer Abstract:Â ...
Read Moreby Raj S. Pruthi, MD, MHA, FACS | May 2022
Raj S. Pruthi, MD, MHA, FACS, Professor in the Department of Urology at the University of California, San Francisco, reviews the American Urological Association (AUA)-Society of Urologic Oncology (SUO) guidelines on diagnosing and treating non-muscle invasive bladder cancer (NMIBC). He begins with some statistics, relating that in 2017, there were approximately 79,000 new cases of bladder cancer, 16,800 deaths, and greater than 500,000 survivors. Dr. Pruthi observes that bladder cancer is a disease of older individuals, and he predicts that the population of bladder cancer patients will increase as the population ages. He then highlights key facts about NMIBC, explaining that most patients recur, some progress, and the ability to predict recurrence and progression is based on patient-specific disease characteristics. Dr. Pruthi introduces the 2016 AUA/SUO guidelines, noting that the panel featured a patient advocate. He goes over the guidelines point by point, starting with diagnosis. Dr. Pruthi underscores the importance of performing a complete visual transurethral resection of bladder tumor (TURBT) at initial diagnosis, explaining that incomplete TURBT is a contributing factor to early recurrences. He notes that risk calculators for NMIBC are limited by lack of applicability to current populations, and also that no study has evaluated the effectiveness of urinary biomarkers to decrease mortality or improve outcomes compared with standard diagnostic methods. When discussing guidelines around treatment, Dr. Pruthi emphasizes the importance of re-resecting T1 disease since understaging occurs in about 30% of cases and patients with residual T1 (after presumed complete resection) have up to an 80% chance of progression. He also discusses guidelines around BCG administration and BCG relapse. Dr. Pruthi then looks at cystectomy, arguing that waiting until progression to muscle invasion may prove fatal. He concludes by discussing guidelines around follow up.
Read More